[go: up one dir, main page]

WO2009103218A8 - Dérivés d'hydrazine carboxamide d'éthylidène, processus de préparation et utilisation pharmaceutique de ceux-ci - Google Patents

Dérivés d'hydrazine carboxamide d'éthylidène, processus de préparation et utilisation pharmaceutique de ceux-ci Download PDF

Info

Publication number
WO2009103218A8
WO2009103218A8 PCT/CN2009/000136 CN2009000136W WO2009103218A8 WO 2009103218 A8 WO2009103218 A8 WO 2009103218A8 CN 2009000136 W CN2009000136 W CN 2009000136W WO 2009103218 A8 WO2009103218 A8 WO 2009103218A8
Authority
WO
WIPO (PCT)
Prior art keywords
preparation process
pharmaceutical use
carboxamide derivatives
ethylidene
hydrazine carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2009/000136
Other languages
English (en)
Chinese (zh)
Other versions
WO2009103218A1 (fr
Inventor
邓炳初
吕贺军
陈一千
宋鹏
王胜蓝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Priority to CN2009800002470A priority Critical patent/CN101679242B/zh
Publication of WO2009103218A1 publication Critical patent/WO2009103218A1/fr
Publication of WO2009103218A8 publication Critical patent/WO2009103218A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/40—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des dérivés d'hydrazide carboxamide d'éthylidène représentés par la formule (I) ou des sels, un hydrate ou un solvate pharmaceutiquement acceptables de ceux-ci, des procédés de préparation de ces dérivés, des compositions pharmaceutiques les contenants et leur utilisation comme agent thérapeutique, en particulier comme mimétiques de thrombopoïétine (TPO) et leur utilisation comme agonistes du récepteur de thrombopoïétine. Les définitions des substituants dans la formule (I) sont telles que présentées dans la description.
PCT/CN2009/000136 2008-02-21 2009-02-06 Dérivés d'hydrazine carboxamide d'éthylidène, processus de préparation et utilisation pharmaceutique de ceux-ci Ceased WO2009103218A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2009800002470A CN101679242B (zh) 2008-02-21 2009-02-06 亚乙基肼酰胺类衍生物、其制备方法及其在医药上的应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA2008100061796A CN101514179A (zh) 2008-02-21 2008-02-21 吲哚酮亚乙基肼羰基化合物、其制备方法及其在医药上的应用
CN200810006179.6 2008-02-21

Publications (2)

Publication Number Publication Date
WO2009103218A1 WO2009103218A1 (fr) 2009-08-27
WO2009103218A8 true WO2009103218A8 (fr) 2009-12-03

Family

ID=40985060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/000136 Ceased WO2009103218A1 (fr) 2008-02-21 2009-02-06 Dérivés d'hydrazine carboxamide d'éthylidène, processus de préparation et utilisation pharmaceutique de ceux-ci

Country Status (2)

Country Link
CN (2) CN101514179A (fr)
WO (1) WO2009103218A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049213A1 (fr) * 2009-10-23 2011-04-28 日産化学工業株式会社 Composés hétérocycles fusionnés et activateur du récepteur de la thrombopoïétine
EP2780322B1 (fr) 2011-11-14 2018-05-16 Ligand Pharmaceuticals, Inc. Procédés et compositions associés au récepteur du facteur de stimulation des colonies de granulocytes
WO2014150252A1 (fr) * 2013-03-15 2014-09-25 Ligand Pharmaceuticals Incorporated Méthodes de traitement associées au récepteur du facteur de stimulation des colonies de granulocytes
CN104628647A (zh) * 2013-11-12 2015-05-20 上海医药工业研究院 3-甲基-1-(3,4-二甲基苯基)-2-吡唑啉-5-酮的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032916A2 (fr) * 2001-10-16 2003-04-24 Structural Bioinformatics Inc. Organosulfures inhibiteurs de tyrosine phosphatases
TWI324593B (en) * 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
WO2006028970A1 (fr) * 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derives d'inhibiteurs de thiazole et de thiadiazole de tyrosine phosphatases
TWI399368B (zh) * 2004-12-14 2013-06-21 Nissan Chemical Ind Ltd Amide compounds and thrombopoietin receptor activators
KR20080080305A (ko) * 2005-11-23 2008-09-03 리간드 파마슈티칼스 인코포레이티드 트롬보포이에틴 활성 조절 화합물 및 이의 조절 방법

Also Published As

Publication number Publication date
CN101679242B (zh) 2013-07-10
WO2009103218A1 (fr) 2009-08-27
CN101679242A (zh) 2010-03-24
CN101514179A (zh) 2009-08-26

Similar Documents

Publication Publication Date Title
MX2010007553A (es) Derivados de azopirazolona biciclo-sustituidos, procedimiento de preparacion y uso farmaceutico de los mismos.
MX2009006474A (es) Derivados de benzamida como agonistas del receptor ep4.
MX2011012639A (es) Sales de derivados de pirazolon azo sustituidos con biciclo, metodo de preparacion y uso de los mismos.
WO2008048981A3 (fr) Antagonistes d'indole du récepteur p2y1 utiles dans le traitement d'états thrombotiques
WO2008039489A3 (fr) Dérivés de quinazolinone substitués en 5', compositions contenant ces dérivés et procédés d'utilisation
WO2008010921A3 (fr) Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques
MY146645A (en) Purine derivatives for use as adenosin a2a receptor agonists
MY149622A (en) Pyrazoles as 11-beta-hsd-1
WO2008006795A3 (fr) Composés d'indole
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
MX2009013078A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato - 842.
WO2008135791A8 (fr) Imidazoquinolines dotées de propriétés immuno-modulatrices
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
TNSN08544A1 (en) Purine derivatives as a2a agonists
WO2007065808A3 (fr) Agonistes du récepteur du neuropeptide-2
WO2007150026A3 (fr) Dérivés de purinone en tant qu'agonistes de hm74a
WO2011045232A3 (fr) Agonistes du récepteur du neuropeptide-2 (y-2r)
WO2007120575A3 (fr) Agonistes du récepteur de la niacine, compositions contenant de tels composés et méthodes de traitement
WO2007150025A3 (fr) Dérivés de purinone en tant qu'agonistes du hm74a
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
MX2008013040A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980000247.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09713556

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09713556

Country of ref document: EP

Kind code of ref document: A1